TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30676838
Drug: Medium-dose investigational
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose investigational Sabin IPV (group B)
Study: 30676838
Drug: Low-dose investigational
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose investigational Sabin IPV (group C)
Study: 20878446
Drug: Protracted dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protracted dose-dense temozolomide therapy (100 mg/m² for 21 consecutive days of a 28-day cycle)
Study: 20878446
Drug: Protracted dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protracted dose-dense temozolomide therapy
Study: 19170737
Drug: Clobazam (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (high dose = target 1.0 mg/kg/day)
Study: 19170737
Drug: Clobazam (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (low dose = target 0.25 mg/kg/day)
Study: 19170737
Drug: Clobazam (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (high dose)
Study: 19170737
Drug: Clobazam (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (low dose)
Study: 19170737
Drug: Clobazam (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (both doses)
Study: 14767877
Drug: 1.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/d n3PUFA
Study: 14767877
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g n3PUFA + 800 IU/d AT
Study: 11411195
Drug: Bio-Hep (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-Hep (10 micrograms dose)
Study: 11411195
Drug: Engerix-B (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B (20 micrograms dose)
Study: 10064661
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zafirlukast
Study: 10064661
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zafirlukast
Study: 10064661
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zafirlukast
Study: 10064661
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg zafirlukast
Study: 10064661
Drug: All zafirlukast
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All zafirlukast doses
Study: 7656832
Drug: Cimetidine (CMD)
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine (CMD) in combination with radiation therapy
Study: 19539180
Drug: Fish-oil concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil concentrate supplementation (six 1-g soft-gel capsules daily for 6 months)
Study: 19539180
Drug: Corn-oil capsules
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn-oil capsules (same protocol as fish-oil group)
Study: 9028091
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural lidocaine (1% lidocaine 5ml.h‐1) during surgery combined with preoperative epidural morphine (2 mg)
Study: 9028091
Drug: Preoperative epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative epidural morphine (2 mg) alone
Study: 2565998
Drug: Killed hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed hepatitis A vaccine with aluminium hydroxide as adjuvant
Study: 2565998
Drug: Killed hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed hepatitis A vaccine without aluminium hydroxide as adjuvant
Study: 2565998
Drug: Killed hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed hepatitis A vaccine (both groups)
Study: 946973
Drug: Alice influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alice influenza virus vaccine
Study: 946973
Drug: Ultraviolet inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraviolet inactivated vaccine
Study: 946973
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antibody-negative)
Study: 27862855
Drug: Oxytocin 30
Normalized name: oxytocin 30 units/500 mL-5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 30 IU in 500 ml normal saline
Study: 15079129
Drug: Taxanes and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxanes and irinotecan in combinations with platinum compounds and fluoropyrimidines
Study: 3730530
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of diethylamine chromocarbe 0.5 h before breakfast
Study: 3730530
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of diethylamine chromocarbe at lunch
Study: 3730530
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of diethylamine chromocarbe before dinner
Study: 29716702
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (beta blockers, ACEI, diuretics)
Study: 27834812
Drug: High-Intensity Interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Interval Training (HIIT) with weekly motivational encouragement through text messages and access to a study website
Study: 24162260
Drug: Denosumab 120
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 120 mg subcutaneously monthly
Study: 24162260
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg intravenously monthly
Study: 22493422
Drug: Tivozanib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib 1.5 mg/d for 16 weeks
Study: 17538086
Drug: Temsirolimus (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (25 mg intravenous weekly)
Study: 20461090
Drug: Interferon-alpha (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (titrated to 18 mU three times weekly)
Study: 20461090
Drug: Temsirolimus (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (15 mg intravenous weekly) plus interferon-alpha (6 mU three times weekly)
Study: 19087296
Drug: Oral calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral calcitonin
Study: 8607670
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 g before incision)
Study: 8607670
Drug: Control (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (250 mL placebo saline solution)
Study: 23072844
Drug: Lignocaine hydrochloride
Normalized name: Lignocaine hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine hydrochloride without adrenaline (xylocaine 2%) - 2 mL
Study: 23072844
Drug: Lignocaine hydrochloride
Normalized name: Lignocaine hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine hydrochloride with adrenaline 1:80,000 - 2 mL
Study: 17969889
Drug: Shenyin Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenyin Oral Liquid (SOL)
Study: 14985689
Drug: MUFA meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MUFA meal (40 g MUFA; 12 g SFA)
Study: 14985689
Drug: SFA meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFA meal (20 g MUFA; 32 g SFA)
Study: 11440963
Drug: Oltipraz given
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz given daily at 125 mg p.o.
Study: 11440963
Drug: Oltipraz given
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz given once per week at 500 mg p.o.
Study: 9730996
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone (500 microgram twice daily)
Study: 7762842
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion
Study: 31089014
Drug: IV sugammadex
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV sugammadex 2 mg.kg‐1
Study: 31089014
Drug: Neostigmine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.04 mg.kg‐1 + atropine 0.01 mg.kg‐1
Study: 23021205
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention combined with daily low-glycaemic index meal replacement
Study: 16933235
Drug: HCV-Ab(XTL)68 120
Normalized name: Crotalidae immune F(ab')2 (equine) 120 MG [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV-Ab(XTL)68 120 mg
Study: 16933235
Drug: HCV-Ab(XTL)68 240
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV-Ab(XTL)68 240 mg
Study: 16933235
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments combined
Study: 15309392
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment (initial dose of 20mg, with increments to a maximum of 60 mg over 8 weeks)
Study: 9406266
Drug: Standard-dose olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose olanzapine (5 to 15 mg a day)
Study: 9406266
Drug: Ineffective-dose olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ineffective-dose olanzapine (1 mg a day)
Study: 26198433
Drug: Interprofessional Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interprofessional Medication Therapy Management (MTM) approach
Study: 23916488
Drug: Ranibizumab (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (0.50 mg)
Study: 20233526
Drug: Ningdong (ND)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningdong (ND) granule, 1 g/kg per day, n = 33
Study: 16809911
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (1.5 pmol/kg x min)
Study: 25193531
Drug: Gla‐300 (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gla‐300 (insulin glargine 300 units/mL)
Study: 25193531
Drug: Gla‐100 (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gla‐100 (insulin glargine 100 units/mL)
Study: 20106943
Drug: Glatiramer Acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer Acetate (GA) therapy
Study: 17555412
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser (L-group)
Study: 8851647
Drug: Standard neuroleptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard neuroleptic therapy
Study: 31033232
Drug: Group-based outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based outpatient physical therapy (PT) intervention (6 sessions)
Study: 30871514
Drug: Green cardamom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green cardamom (GC) supplementation, 500 mg capsules, 3 times/day for 3 months
Study: 14996517
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg once daily for 10 days
Study: 12198820
Drug: Various drugs
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various drugs evaluated in RCTs since the 1970s for diabetic neuropathy treatment.
Study: 12198820
Drug: Drugs for
Normalized name: DRUGS FOR CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for diabetic neuropathy treatment.
Study: 2172280
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (10 mg/kg.day) for 7-14 days
Study: 31858673
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec or insulin glargine U100
Study: 15911951
Drug: Nebulised bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised bronchodilator (terbutaline)
Study: 10670125
Drug: BCG 27
Normalized name: BCG 27 mg intravesical powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG 27 mg weekly x 6 and monthly until complete one year (Group A)
Study: 10670125
Drug: BCG plus
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG plus Tegafur 800 mg daily until complete one year (Group B)
Study: 8601654
Drug: 40% trichloroacetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% trichloroacetic acid (TCA) chemical peel with topical tretinoin pretreated for 6 weeks and used after the peel
Study: 2021877
Drug: Acarosan treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarosan treatment group (cleaning + benzylbenzoate)
Study: 2021877
Drug: Intensive cleaning
Normalized name: STANNOUS FLUORIDE 1.4 mg in 1 g DENTAL PASTE, DENTIFRICE [Crest Pro Health Advanced Whitening Intensive Cleaning]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive cleaning without acaricidal treatment
Study: 6805019
Drug: Sedative-hypnotics (Benzodiazepine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative-hypnotics (Benzodiazepine hypnotics)
Study: 22555398
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and S-1 combination therapy
Study: 19170225
Drug: Epoetin-alpha initiated
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-alpha initiated when hemoglobin decreased to <11 g/dL (standard intervention)
Study: 12133465
Drug: H(2) vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H(2) vaccine
Study: 12133465
Drug: LA-1 vaccine
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA-1 vaccine
Study: 20872359
Drug: 0.5% carboxymethylcellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% carboxymethylcellulose and 0.9% glycerin (CMCs) administered QID
Study: 20872359
Drug: 0.2% sodium
Normalized name: Dextrose 5% and 0.2% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% sodium hyaluronate (SH) administered QID
Study: 11459079
Drug: Famotidine 2
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 2 mg/kg/day (maximum 100 mg)
Study: 7920221
Drug: Intravenous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous methotrexate (MTX) 5 g/m2 as a 24 hour-infusion
Study: 17848682
Drug: Revascularization treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revascularization treatment
Study: 26632893
Drug: Reverse hybrid
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reverse hybrid therapy (pantoprazole plus amoxicillin for 12 days and clarithromycin plus metronidazole for the initial 7 days)
Study: 26632893
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (pantoprazole plus amoxicillin and clarithromycin for 12 days)
Study: 23127191
Drug: Fentanyl analgesics
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl analgesics
Study: 23127191
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional care and treatment)
Study: 21045648
Drug: Omega-3 supplement
Normalized name: Systane Vitamin Omega-3 Supplement Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplement (daily dose of fish oil: 450 mg eicosapentaenoic acid, 300 mg docosahexaenoic acid, 1000 mg flaxseed oil) for 90 days
Study: 28707491
Drug: Omega-3 supplement
Normalized name: Systane Vitamin Omega-3 Supplement Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplement
Study: 16784009
Drug: 75000 standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75000 standardized quality tablet (SQ-T) units
Study: 8983091
Drug: Intranasal cholecystokinin‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cholecystokinin‐8 (CCK) 10 micrograms
Study: 8983091
Drug: Intravenous cholecystokinin‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cholecystokinin‐8 (CCK) 0.25 micrograms
Study: 8983091
Drug: Intravenous cholecystokinin‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cholecystokinin‐8 (CCK) 2.5 micrograms
Study: 8983091
Drug: Intranasal cholecystokinin‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cholecystokinin‐8 (CCK)
Study: 1458715
Drug: Flurbiprofen-SR 200
Normalized name: flurbiprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen-SR 200 mg
Study: 1458715
Drug: Diclofenac Sodium-SR
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac Sodium-SR 100 mg
Study: 31536957
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care arm of the Pain Program for Active Coping and Training (PPACT) study, involving opioid treatment under monitoring.
Study: 28753781
Drug: PSA and
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA and Digital Rectal Examination (DRE)
Study: 27106691
Drug: F0.5 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: F0.5 group (0.5 μg.kg(‐1) fentanyl)
Study: 27106691
Drug: F1.0 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: F1.0 group (1.0 μg.kg(‐1) fentanyl)
Study: 24598244
Drug: GAD65 vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD65 vaccination with GAD-alum (twice subcutaneously at intervals of 4 weeks)
Study: 21680782
Drug: Subcutaneous or
Normalized name: Vaccinia, smallpox monkeypox vaccine, live attenuated, preservative free, subcutaneous or intradermal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous or intramuscular PEG‐IFN beta‐1a (63, 125, or 188 µg)
Study: 21680782
Drug: Subcutaneous PEG‐IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous PEG‐IFN beta‐1a dosed once every 2 or 4 weeks
Study: 21680782
Drug: Intramuscular unmodified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular unmodified IFN beta‐1a 30 µg
Study: 16201177
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ciprofloxacin (0.5 g) and metronidazole (0.4 g)
Study: 16201177
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ciprofloxacin (0.5 g) and metronidazole (0.4 g) twice a day for 3 days
Study: 16201177
Drug: Placebo (Vit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Vit C) tablet twice a day for 3 days
Study: 3052691
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg daily for 3 months
Study: 3052691
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily for 3 months
Study: 3052691
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg daily for 6 months
Study: 3052691
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily for 6 months
Study: 27592112
Drug: Neoadjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant systemic therapy (NAC)
Study: 21305729
Drug: Intravitreal Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Bevacizumab (IVB) 1.25 mg/0.05 mL
Study: 21305729
Drug: Intravitreal Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Bevacizumab and Triamcinolone (IVB/IVT) 1.25 mg/0.05 mL and 2 mg/0.05 mL
Study: 18251159
Drug: 30‐min Pringle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30‐min Pringle maneuver with gabexate mesilate (GM, 2 mg/kg/h)
Study: 18251159
Drug: 15‐min Pringle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15‐min Pringle maneuver with gabexate mesilate (GM, 2 mg/kg/h)
Study: 8574280
Drug: Ephedrine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (30 mg)
Study: 8574280
Drug: Nadolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (2.5 mg)
Study: 8574280
Drug: Nadolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (5 mg)
Study: 8574280
Drug: Nadolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (10 mg)
Study: 9693348
Drug: Cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive treatment
Study: 22829944
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of statins (rosuvastatin or atorvastatin) and regular exercise
Study: 19168602
Drug: Levetiracetam (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (250 mg/day to 2000 mg/day for 6 weeks)
Study: 30865791
Drug: Short regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short regimen (9 to 11 months) including high-dose moxifloxacin
Study: 15235926
Drug: Baked skim
Normalized name: skim milk
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baked skim soy with soy sauce (protein, 86.9 g)
Study: 15235926
Drug: Beefsteak (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beefsteak (200 g)
Study: 10980457
Drug: Regular fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular fluticasone (250 microg twice daily for two weeks)
Study: 10980457
Drug: Single fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single fluticasone (250 microg 30 min before allergen inhalation)
Study: 2413692
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin applied under occlusion